These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26063677)

  • 1. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine.
    Epperson CN; Shanmugan S; Kim DR; Mathews S; Czarkowski KA; Bradley J; Appleby DH; Iannelli C; Sammel MD; Brown TE
    Psychopharmacology (Berl); 2015 Aug; 232(16):3091-100. PubMed ID: 26063677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisdexamfetamine Effects on Executive Activation and Neurochemistry in Menopausal Women with Executive Function Difficulties.
    Shanmugan S; Loughead J; Nanga RP; Elliott M; Hariharan H; Appleby D; Kim D; Ruparel K; Reddy R; Brown TE; Epperson CN
    Neuropsychopharmacology; 2017 Jan; 42(2):437-445. PubMed ID: 27550732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD.
    Adler LA; Leon TL; Sardoff TM; Krone B; Faraone SV; Silverstein MJ; Newcorn JH
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34232582
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
    Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
    J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
    BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
    Martin PT; Corcoran M; Zhang P; Katic A
    Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women.
    Epperson CN; Pittman B; Czarkowski KA; Bradley J; Quinlan DM; Brown TE
    Menopause; 2011 May; 18(5):542-8. PubMed ID: 21293309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
    Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
    [No Abstract]   [Full Text] [Related]  

  • 11. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.
    Madhoo M; Keefe RS; Roth RM; Sambunaris A; Wu J; Trivedi MH; Anderson CS; Lasser R
    Neuropsychopharmacology; 2014 May; 39(6):1388-98. PubMed ID: 24309905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.
    Morrow SA; Smerbeck A; Patrick K; Cookfair D; Weinstock-Guttman B; Benedict RH
    J Neurol; 2013 Feb; 260(2):489-97. PubMed ID: 23001556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
    Turgay A; Ginsberg L; Sarkis E; Jain R; Adeyi B; Gao J; Dirks B; Babcock T; Scheckner B; Richards C; Lasser R; Findling RL
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):503-11. PubMed ID: 21186969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
    Brown TE; Brams M; Gasior M; Adeyi B; Babcock T; Dirks B; Scheckner B; Wigal T
    Curr Med Res Opin; 2011; 27 Suppl 2():23-33. PubMed ID: 21973229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA; Alperin S; Leon T; Faraone S
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
    J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.